Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis

米拉贝格伦 膀胱过度活动 医学 安慰剂 荟萃分析 随机对照试验 不利影响 排尿 托特罗定 夜尿症 泌尿科 内科学 泌尿系统 替代医学 病理
作者
Wenjuan He,Yuqian Zhang,Guangliang Huang,Yunfei Tian,Qian Sun,Xiuju Liu
出处
期刊:Luts: Lower Urinary Tract Symptoms [Wiley]
卷期号:15 (3): 80-88 被引量:5
标识
DOI:10.1111/luts.12475
摘要

Abstract Objectives The aim of this study was to indirectly compare the efficacy and safety of mirabegron and vibegron in patients with overactive bladder. Methods A systematic search was performed on Pubmed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials databases to identify studies from the date of database inception to January 1, 2022. All randomized controlled trials comparing mirabegron or vibegron with tolterodine, imidafenacin, or placebo were eligible. One reviewer extracted data, and a second reviewer checked. Included trials were assessed for similarity, and networks were developed using Stata 16.0 software. Mean differences for continuous variables and odds ratios for dichotomous variables together with their 95% confidence intervals (CIs) were used to rank treatments and compare the differences, respectively. Results A total of 11 randomized controlled trials and 10 806 patients were included. For each outcome, results for all licensed treatment doses were included. Both vibegron and mirabegron were more efficacious than placebo at reducing the frequency of micturition, incontinence, urgency, urgency incontinence, and nocturia. Vibegron was more efficacious than mirabegron in reducing mean voided volume/micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo. Conclusions Both drugs seem to be comparable and well tolerated, particularly as direct comparisons are not available. However, vibegron may be more effective than mirabegron in reducing mean voided volume.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小熊发布了新的文献求助10
1秒前
1秒前
无聊的熠彤完成签到 ,获得积分10
1秒前
1秒前
稳重飞飞完成签到,获得积分10
1秒前
苗条的千易完成签到,获得积分10
2秒前
3秒前
xiaowan完成签到,获得积分10
3秒前
宜醉宜游宜睡应助ronnie采纳,获得10
3秒前
烟花应助米里迷路采纳,获得10
3秒前
思源应助yaya采纳,获得10
4秒前
4秒前
双夏完成签到 ,获得积分10
5秒前
9秒前
hygge发布了新的文献求助10
9秒前
10秒前
brd发布了新的文献求助10
10秒前
英俊的铭应助小熊采纳,获得10
10秒前
爆米花应助VV采纳,获得10
11秒前
11秒前
骑着火车撵火箭完成签到,获得积分10
12秒前
成就的白竹完成签到,获得积分10
12秒前
Demon发布了新的文献求助10
13秒前
Alex发布了新的文献求助10
13秒前
13秒前
sci01完成签到 ,获得积分10
14秒前
超帅天曼完成签到,获得积分10
14秒前
kekao完成签到,获得积分10
15秒前
15秒前
YGTRECE发布了新的文献求助10
15秒前
阿包完成签到 ,获得积分10
16秒前
科研顺荔发布了新的文献求助10
17秒前
舟舟发布了新的文献求助10
17秒前
大方的天晴完成签到,获得积分10
18秒前
油炸小酥肉完成签到,获得积分10
18秒前
YYJJ发布了新的文献求助10
18秒前
称心的飞烟完成签到,获得积分20
18秒前
桐桐应助20182531027采纳,获得10
19秒前
19秒前
CipherSage应助Liao采纳,获得10
19秒前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 800
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3053572
求助须知:如何正确求助?哪些是违规求助? 2710765
关于积分的说明 7423161
捐赠科研通 2355230
什么是DOI,文献DOI怎么找? 1246916
科研通“疑难数据库(出版商)”最低求助积分说明 606188
版权声明 595975